A significant relationship between plasminogen activator inhibitor type-1 and lipoprotein(a) in non-insulin-dependent diabetes mellitus without complications

International Journal of Clinical and Laboratory Research

Volumn 28, Issue 3, 1998, Pages 187-191

  Testa, R ^a   Bonfigli, A R ^a   Pieri, C ^a   Marra, M ^a   Sirolla, C ^a   Manfrini, S ^b   Testa, I ^b  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Diabetes mellitus; Diabetic complications; Fibrinolysis; Lipoprotein(a); Plasminogen activator inhibitor type 1

Indexed keywords

LIPOPROTEIN A; PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; FEMALE; FIBRINOLYSIS; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AGED; ANALYSIS OF VARIANCE; DIABETES MELLITUS, TYPE 2; FEMALE; FIBRINOLYSIS; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED; PLASMINOGEN ACTIVATORS;

EID: 0031692988     PISSN: 09405437     EISSN: None     Source Type: Journal    
DOI: 10.1007/s005990050042     Document Type: Article

References (39)

1. Wiman B, Hamsten A. The fibrinolytic enzyme system and us role in the etiology of thromboembolic disease. Semin Thromb Hemost 1990; 16: 207.
2. Smith EB. Haemostatic factors and atherogenesis. Atherosclerosis 1996; 124: 137.
3. Schneider DJ, Nordt TK, Sobel BE. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993; 42: 1.
4. Levin EG. Quantitation and properties of the active and latent plasminogen activator inhibitors in cultures of human endothelial cells. Blood 1986; 67: 1309.
5. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381.
6. Koschinsky LM, Marcovina SM. Lipoprotein(a): structural implications for pathophysiology. Int J Clin Lab Res 1997; 27: 14.
7. Scanu AM. Lipoprotein(a). Bailleres Clin Endocrinol Metab 1990; 4: 939
8. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68.
9. Hancu N, Netea MG, Iancu S Serum lipoprotein(a) is increased in hypertensive NIDDM patients. Diabetes Care 1995; 18: 879.
10. Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Yamazaki M, Aoshima K, Hashimoto T, Matsuda T. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120: 7.
11. Park YS, Park S, Kim SY, Lee HK, Koh CS, Min HK, Kim JQ. The effect of obesity on fibrinolytic activity and plasma lipoprotein(a) levels in patients with type 2 diabetes mellitus in Korea. Diabetes Res Clin Pract 1994; 24: 25
12. Ho CH, Jap TS. Relationship of plasminogen activator inhibitor-1 with plasma insulin, glucose, triglyceride and cholesterol in Chinese patients with diabetes. Thromb Res 1993; 69: 271.
13. Vukovich T, Schernthaner G. The effect of insulin treatment on the balance between tissue plasminogen activator and plasminogen activator inhibitor-1 in type 2 diabetic patients Thromb Haemost 1992; 68: 253.
14. Jokaji H, Asakura H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Matsuda T. Tissue-type plasminogen activator and its inhibitor (PAI-1) in plasma in cases of non-insulin-dependent diabetes mellitus (NIDDM). Nippon Ronen Igakkai Zasshi 1990; 27: 699.
15. Joven J, Vilella E. Serum levels of lipoprotein(a) in patients with well controlled non insulin dependent diabetes mellitus. JAMA 1991; 265: 1113.
16. Testa R, Bonfigli AR, Piantanelli L, Manfrini S, Testa I, Gregorio F. Relationship between plasminogen activator inhibitor type I plasma levels and the lipoprotein(a) concentrations in non insulin dependent diabetes mellitus. Diabetes Res Clin Pract 1996; 33: 111.
17. Huisveld IA, Leenen R, Kooy K vd, Hospers JEH, Seidell JC, Deurenberg P, Koppeschaar HPF, Mosterd WL, Bouma BN. Body composition and weight reduction in relation to antigen and activity of plasminogen activator inhibitor (PAI-1) in overweight individuals. Fibrinolysis 1990; 4: 84.
18. Oseroff A, Krishnamurti C, Hassett A, Tang D, Alving B. Plasminogen activator and plasminogen activator inhibitor activities in men with coronary artery disease. J Lab Clin Med 1989; 113: 88.
19. Ceriello A, Curcio F, Russo P dello, Pegoraro I, Stel G, Amstad P, Cerutti P. The defense against free radicals protects endothelial cells from hyperglycaemia-induced plasminogen activator inhibitor 1 over-production. Blood Coagul Fibrinolysis 1995; 6: 133.
20. Trifiletti A, Barbera M, Pizzoleo MA, Lasco A, Lucifora S, Leone G, Soracie S, Pedulla M, Frisina M. Hemostatic variables in arterial hypertension. Haemostasis 1995; 25: 237.
21. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 25: 245.
22. Ligthart GJ, Corberand JX, Fournier C, Galanaud P, Hijman W, Kennes B, Muller-Hermelink HK, Steimann GG. Admission criteria for immunogerontological studies in man: the SENIEUR protocol. Mech Ageing Dev 1984; 28: 47.
23. Declerk PJ. Multicenter evaluation of commercially available methods for the immunological determination of plasminogen active or inhibitor-1 (PAI-1) Thromb Haemost 1993; 70: 858.
24. Juan-Vague I, Moerman B, De Cock F, Aillaud MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523.
25. Cao G, Alessio HM, Cutler RG. Oxygen-radical absorbance capacity assay for antioxidants. Free Radic Biol Med 1993; 14: 303.
26. Testa R, Testa I, Manfrini S, Bonfigli AR, Piantanelli L, Marra M, Fieri C. Glycosylated hemoglobin and fructosamines: does their determination really reflect the glycemic control in diabetic patients? Life Sci 1996; 59: 43.
27. Takada Y, Urano T, Watanabe I, Taminato A, Yoshimi T, Takada A. Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus. Thromb Res 1993; 71: 405.
28. Morishita E, Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Yamazaki M, Aoshima K, Hashimoto T, Matsuda T. Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. Atherosclerosis 1996; 120: 7.
29. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R. Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 1996; 16: 471.
30. Gray RP, Hydkin JS, Patterson DL. Plasminogen activator inhibitor: a risk factor for myocardial infarction in diabetic patients. Br Heart J 1992; 69: 228.
31. Utermann G, Menzel HJ, Kraft HG, Duaba HC, Kemmler HG, Seitz C. Lp(a) glycoprotein phenotypes inheritance and relation to Lp(a). lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458.
32. Sonnichsen AC, Richler WO, Schwandt P. Reduction of lipoprotein(a) by weight loss. Int J Obes 1990; 14: 487.
33. Kervinen K, Savolainen MJ, Kesaniemi YA. A rapid increase in lipoprotein(a) levels after ethanol withdrawal in alcoholic men. Life Sci 1991; 48: 2183.
34. Boyer H, Gennes JL de, Truffert J, Chatellier G, Dairou F, Bruckert E. Lp(a) levels in different types of dyslipidemia in the French population. Atherosclerosis 1990; 85: 61.
35. Juhan-Vague I, Vague P, Alessi MC, Badier C, Valadier J, Aillaud MF. Relationships between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metab 1987; 13: 331.
36. Mussoni L, Mannucci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Artherioscler Thromb 1992; 12: 19.
37. Medina R, Socher SH, Han JH, Friedman PA. Interleukin-1, endotoxin or tumor necrosis factor/cachectin enhance the level of plasminogen activator inhibitor messenger RNA in bovine aortic endothelial cells. Thromb Res 1989; 54: 41.
38. Gris JC, Schved JF, Aguilar-Martinez P, Arnaud A, Sanchez N. Impact of physical training on plasminogen activator inhibitor activity in sedentary men. Fibrinolysis 1990; 4: 97.
39. Vicari AM, Viganò D'Angelo S, Testa S, Comi G, Garlardi G, Orsi E, D'Angelo A. Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type I diabetes mellitus. Horm Metab Res 1991; 24: 516.